Search results for abx831293

Lifastuzumab, Abbexa, abx831293

Lifastuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SLC34A2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).